MedinCell: SAIVE Study data to be presented at ECCMID 2023 Euronext: MEDCL
April 17, 2023
Previous PostTeva and MedinCell Announce FDA Approval of UZEDY™ (risperidone) Extended-Release Injectable Suspension, a Long-Acting Subcutaneous Atypical Antipsychotic Injection, for the Treatment of Schizophrenia in Adults
Next PostMedinCell announces the initiation of coverage of its stock by Portzamparc - BNP Paribas Group
